Overview

A Phase 1a/1b FIH Study of PY265 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is an open-label, multicenter, first in human phase 1a/1b study of PY265 in subjects with locally advanced (unresectable) and/or metastatic solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Pionyr Immunotherapeutics Inc.